Biotech News

Aclaris Therapeutics to Participate in Three November Healthcare Conferences

Aclaris Therapeutics (ACRS)Aclaris TherapeuticsConference / presentation

Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that the Company will participate in three upcoming healthcare conferences in November.

On Wednesday November 12, 2025, at 11:00 AM EST, Aclaris’ Chief Executive Officer Dr. Neal Walker and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Guggenheim 2 nd Annual Healthcare Conference in Boston, MA.

On Wednesday November 12, 2025, at 1:20 PM EST, Aclaris’ President and Chief Operating Officer Dr. Hugh Davis and other members of Aclaris’ senior leadership team will participate in a fireside chat during the Stifel 2025 Healthcare Conference in New York, NY.

On Monday November 17, 2025, at 2:00 PM GMT (9:00 AM EST), Dr. Walker will participate in a fireside chat during the Jefferies Global Healthcare Conference in London, UK.

Live and archived webcasts of these events will be accessible on the Events page of https://www.aclaristx.com/ . The webcasts will be available on the Aclaris website for at least 30 days.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel product candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of product candidates powered by a robust R&D engine. For additional information, please visit www.aclaristx.com and follow Aclaris on X (formerly Twitter) at @AclarisTx and on LinkedIn .

Aclaris Therapeutics Contact:

Will Roberts Senior Vice President Corporate Communications and Investor Relations (484) 329-2125 [email protected]

Related news

Aclaris Therapeutics

Immuno-Inflammatory Drug Development Aclaris Therapeutics develops biologic and oral therapies for immuno-inflammatory diseases. Its portfolio targets upstream cytokines and intracellular signaling pathways. ATI-052 ATI-052 is a long-acting bispecific antibody against TSLP and IL-4 receptor alpha in proof-of-concept studies for asthma...

Recent company news

Stock data

Close
6.41 USD
Market cap
646.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States